RainDance Technologies Unveils Breakthrough In Somatic Cancer Analysis With Thunderbolts™ Sequencing Panel To Profile Actionable Cancer Mutations For Total Sample Cost As Low As $100
Published: Feb 10, 2014
BILLERICA, Mass.--(BUSINESS WIRE)--RainDance Technologies, Inc., an innovative genomics tools company ‘democratizing’ molecular testing of complex diseases, today announced that it has developed a comprehensive next-generation sequencing (NGS) panel for profiling actionable cancer mutations, enabling researchers to rapidly and cost-effectively analyze precious biopsy specimens. The ThunderBolts™ Cancer Panel targets 49 known cancer genes, including tumor suppressors, hotspots and drug resistance markers, and features industry breakthroughs in performance, sample flexibility, workflow, and cost.
Help employers find you! Check out all the jobs and post your resume.